PharmiNews

Directory of Pharma Companies and News

Company Profile

SurgiMab

SurgiMab logo
Category
SurgiMab is a clinical-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach designed to improve cancer surgery and clinical outcomes for patients. The Company’s lead product SGM-101 comprises a tumor-specific antibody that targets carcinoembryonic antigen (CEA), conjugated to a dye (fluorophore) that fluoresces under near-infra-red (700nm) light. SGM-101 is in a pivotal Phase 3 trial in colorectal cancer (CRC) patients. Safety and effectiveness of SGM-101 have both been demonstrated in Phase 1 and Phase 2 clinical trials in patients undergoing surgery for colorectal cancer. SurgiMab is planning to develop SGM-101 and, pending approval, intends to launch and commercialize this specialty product together with partners in selected markets. SurgiMab was founded in 2011 and is a privately-owned company headquartered in Montpellier (France).
Keywords:
0 results
Brought to you by PharmiWeb.com - Latest Jobs in Pharma